Warar Degdeg ah
Saynis

Shirkadda MSICS Pharma Oo Helaysa $3.6 Milyan Si Ay U Balaadhiso Tijaabooyinka Dawooyinka Psychedelic-ka Ah

Shirkadda Israa'iil ee Msics Pharma ayaa heshay $3.6 milyan oo doolar si ay u ballaariso tijaabooyinka caafimaad ee daawaynta psilocybin ee loo isticmaalo niyadjabka iyo OCD.

Yeruusaalem, 3 May, 2026 (TPS-IL) — MSICS Pharma, oo ah shirkad Israa’iili ah oo ku takhasustay horumarinta daawooyinka psilocybin ee heerka caafimaad, ayaa ku dhawaaqday inay urursatay 3.6 milyan oo doolar wareegii maalgelinta oo ay hoggaaminayeen maalgashadayaal ay ku jiraan Fusion VC iyo GlenRock. Shirkaddu waxay sheegtay inay tahay shirkadda kaliya ee ku taal Israa’iil iyo Yurub oo uu Wasaaradda Caafimaadku siiyay ruqsad ay ku soo saarto psilocybin iyadoo la raacayo heerarka Good Manufacturing Practice (GMP) ee isticmaalka caafimaad.

MSICS waxay samaynaysaa tijaabooyin caafimaad oo heerka II ah oo loogu talagalay daawaynta niyadjabka aan u jawaabin daawada iyo cilladda walwal-qabashada (OCD), waxayna qorshaynaysaa inay bilawdo daraasad afar-geesood ah oo ku saabsan PTSD oo ay ka qayb qaadanayaan afar isbitaal oo ku yaal Israa’iil. Shirkaddu waxay sheegtay in maalgelinta cusub ay taageeri doonto kordhinta awoodda wax-soo-saarka, tijaabooyinka caafimaad, iyo diyaarinta gelitaanka suuqyada caalamiga ah.

author avatar
Pesach Benson